Multivariate logistic regression analysis of factors influencing efficacy
| B | SE | Wald | df | P value | OR | 95% CI for OR | ||
| Lower | Upper | |||||||
| Primary efficacy analysis: comorbidities associated with primary non-response during the induction phase* | ||||||||
| IBD | −0.54 | 0.24 | 5.09 | 1 | 0.024 | 0.59 | 0.37 | 0.93 |
| Corticosteroids | 0.77 | 0.28 | 7.66 | 1 | 0.006 | 2.16 | 1.25 | 3.73 |
| Chronic obstructive pulmonary disease | 0.98 | 0.35 | 7.70 | 1 | 0.006 | 2.67 | 1.33 | 5.35 |
| Primary efficacy analysis: comorbidities associated with loss of response during the maintenance phase† | ||||||||
| IBD | −0.54 | 0.27 | 4.05 | 1 | 0.044 | 0.58 | 0.34 | 0.99 |
| Corticosteroids | 0.90 | 0.30 | 8.67 | 1 | 0.003 | 2.45 | 1.35 | 4.44 |
| Myocardial infarction | 1.20 | 0.41 | 8.57 | 1 | 0.003 | 3.30 | 1.48 | 7.35 |
| Secondary efficacy analysis: EIMs associated with primary non-response during the induction phase‡ | ||||||||
| Corticosteroids | 0.73 | 0.27 | 7.32 | 1 | 0.007 | 2.08 | 1.22 | 3.54 |
| Constant | 0.83 | 0.40 | 4.21 | 1 | 0.04 | 2.29 | ||
| Secondary efficacy analysis: EIMs associated with loss of response during the maintenance phase§ | ||||||||
| Corticosteroids | 0.94 | 0.30 | 9.89 | 1 | 0.002 | 2.57 | 1.43 | 4.61 |
| Skin disease | 1.01 | 0.33 | 9.13 | 1 | 0.003 | 2.73 | 1.42 | 5.25 |
*Stepwise MLRA including as independent factors those comorbidities that were significant at p<0.1 in the univariate analysis, and as the dependent factor the primary non-response during the induction phase. In addition, type of IBD, treatment with immunosuppressants, and treatment with corticosteroids were included as fixed factors in the model.
†Stepwise MLRA including as independent factors those comorbidities that were significant at p<0.1 in the univariate analysis, and as the dependent factor the loss of response during the maintenance phase. In addition, type of IBD, treatment with immunosuppressants, and treatment with corticosteroids were included as fixed factors in the model.
‡Stepwise MLRA including as independent factors those EIMs that were significant at p<0.1 in the univariate analysis, and as the dependent factor the primary non-response during the induction phase. In addition, type of IBD, treatment with immunosuppressant, and treatment with corticosteroids were included as fixed factors in the model.
§Stepwise MLRA including as independent factors those EIMs that were significant at p<0.1 in the univariate analysis, and as the dependent factor the loss of response during the maintenance phase. In addition, type of IBD, treatment with immunosuppressants, and treatment with corticosteroids were included as fixed factors in the model.
EIMs, extraintestinal manifestations; IBD, inflammatory bowel disease; MLRA, multivariate logistic regression analysis.